This pamphlet offers reasons to combine tobacco cessation and substance use disorder treatment, including client testimonials and resources for implementing a tobacco cessation program. It also explains the benefits of offering tobacco cessation programs in substance use disorder treatment settings.
You May Also Be Interested In
Implementing Tobacco Cessation Programs in Substance Use Disorder Treatment Settings
This quick guide contains an overview of the challenges associated with tobacco cessation and the benefits of being tobacco-free for individuals as well as those of a smoke-free workplace. It also includes tips that substance use disorder treatment settings can use to implement their own tobacco cessation programs.
Tobacco Use Cessation Policies in Substance Abuse Treatment: Administrative Issues
This resource provides substance use treatment program administrators with information to implement tobacco-free policies and practices in treatment settings. It discusses challenges and strategies for developing clinical guidelines for treating tobacco dependence.
Tobacco Use Cessation During Substance Abuse Treatment Counseling
This advisory offers addiction counselors an introduction to tobacco use cessation during substance use treatment. It discusses screening and effective treatment approaches to quitting, and practical and supportive counseling.
You Can Quit Tobacco
This pamphlet addresses the health benefits that can come with quitting smoking while recovering from substance use disorder.
Incorporating Alcohol Pharmacotherapies Into Medical Practice
This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.
TIP 63: Medications for Opioid Use Disorder - Full Document
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.